Addition of rituximab to the CHOP regimen has no benefit in patients with primary extranodal diffuse large B-cell lymphoma

BACKGROUND: The addition of rituximab to cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) chemotherapy (R-CHOP) has significantly improved clinical outcomes for patients with diffuse large B-cell lymphoma (DLBCL). However, new predictors of patient response to R-CHOP have not been e...

Celý popis

Uloženo v:
Podrobná bibliografie
Hlavní autoři: Jang, Geundoo, Yoon, Dok Hyun, Kim, Shin, Lee, Dae Ho, Lee, Sang-wook, Huh, Jooryung, Suh, Cheolwon
Médium: Artigo
Jazyk:Inglês
Vydáno: Korean Society of Hematology; Korean Society of Blood and Marrow Transplantation; Korean Society of Pediatric Hematology-Oncology; Korean Society on Thrombosis and Hemostasis 2011
Témata:
Original Article
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC3128890/
https://ncbi.nlm.nih.gov/pubmed/21747882
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.5045/kjh.2011.46.2.103
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!

Podobné jednotky